Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Zhao, Xiangxuan ^a   Ogunwobi, Olorunseun O ^a   Liu, Chen ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; MITOGEN ACTIVATED PROTEIN KINASE; NAVITOCLAX; PROTEIN BCL XL; PROTEIN INHIBITOR; SURVIVIN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE; PROTEIN BCL 2; SEPANTRONIUM BROMIDE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; TOXICITY TESTING; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LIVER CELL; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANILINE COMPOUNDS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; HEPATOCYTES; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 79960934681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021980     Document Type: Article

References (41)

1. Danial NN, Korsmeyer SJ, (2004) Cell death: critical control points. Cell 116: 205-219.
2. Fesik SW, (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885.
3. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
4. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
5. Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, et al. (2010) Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 9: 545-557.
6. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66: 869-880.
7. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, et al. (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7: 3265-3274.
8. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14: 3268-3277.
9. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, et al. (2010) Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol 25: 299-307.
10. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, et al. (2007) Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54: 2040-2044.
11. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, et al. (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26: 5198-5203.
12. Kita A, Nakahara T, Takeuchi M, Kinoyama I, Yamanaka K, et al. (2010) [Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155]. Nippon Yakurigaku Zasshi 136: 198-203.
13. Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, et al. (2011) Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res S0145-2126 (10): 00561-8.
14. Wang Q, Chen Z, Diao X, Huang S, (2011) Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Lett S0304-3835 (10): 00566-5.
15. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, et al. (2010) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 10.1111/j.1349-7006.2010.01834.x.
16. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, et al. (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27: 4481-4486.
17. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, et al. (2007) Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133: 1649-1659.
18. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree BC, (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
19. Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R, et al. (2004) Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol 11: 63-69.
20. Yang Y, Zhu J, Gou H, Cao D, Jiang M, et al. (2010) Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol 10.1007/s12032-010-9519-y.
21. Mamori S, Asakura T, Ohkawa K, Tajiri H, (2007) Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol 13: 5306-5311.
22. Yan G, Huang AL, Tang N, Zhang BQ, Pu D, et al. (2003) [Inhibition of survivin expression in liver cancer cells by shRNA]. Zhonghua Gan Zang Bing Za Zhi 11: 712-715.
23. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, et al. (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31: 1080-1085.
24. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021.
25. Jeong JC, Kim MS, Kim TH, Kim YK, (2009) Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells. Neurochem Res 34: 991-1001.
26. Li L, Gao Y, Zhang L, Zeng J, He D, Sun Y, (2008) Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 272: 61-69.
27. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I, (2008) Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 8: 129. 1471-2407-8-129.
28. Jalal HS, Inanami O, Hamasu T, Takahashi M, Kashiwakura I, et al. (2004) Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J Radiat Res (Tokyo) 45: 557-561.
29. Gandhi L, Camidge DR, Ribeiro de OM, Bonomi P, Gandara D, et al. (2011) Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. J Clin Oncol. JCO 2010.31.6208.
30. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66: 869-880.
31. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7: 3265-3274.
32. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14: 3268-3277.
33. Guo XZ, Shao XD, Liu MP, Xu JH, Ren LN, et al. (2002) Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 8: 1059-1062.
34. Garcia EJ, Lawson D, Cotsonis G, Cohen C, (2002) Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol 10: 210-217.
35. Ravazoula P, Tsamandas AC, Kardamakis D, Gogos C, Karatza C, et al. (2002) The potential role of bcl-2 mRNA and protein exression in hepatocellular carcinomas. Anticancer Res 22: 1799-1805.
36. Feng D, Zheng H, Shen M, Cheng R, Yan Y, (1999) [Regulation of p53 and bcl-2 proteins to apoptosis and cell proliferation in liver cirrhosis and hepatocellular carcinoma]. Hunan Yi Ke Da Xue Xue Bao 24: 325-328.
37. Fiorentino M, D'Errico A, Altimari A, Barozzi C, Grigioni WF, (1999) High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. Diagn Mol Pathol 8: 189-194.
38. Takahashi M, Saito H, Okuyama T, Miyashita T, Kosuga M, et al. (1999) Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody-mediated apoptosis. J Hepatol 31: 315-322.
39. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, et al. (2007) Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 67: 3583-3593.
40. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, et al. (2009) Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 15: 3872-3880.
41. Kumar P, Coltas IK, Kumar B, Chepeha DB, Bradford CR, et al. (2007) Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release. Cancer Res 67: 1193-1202.